For instance, the US FDA notes a higher risk of myopathy in patients with decreased or poor function of SLCO1B1 when taking 80 mg of simvastatin6, and CPIC recommends a daily dosage of simvastatin below 20 mg for patients with decreased function of SLCO1B121. This evidence concerns the gene SLCO1B1 and myopathy.